Novo Nordisk
1 / 1
Failed to load
Clinical Trials
New SELECT trial analysis with semaglutide 2.4 mg showed a reduction in hospital admissions with heart disease and overweight
Novo Nordisk
PR-10-24-NI-74Nov 05, 2024
Failed to load
M&A
Novo Holdings Portfolio Company ReViral to be Acquired by Pfizer
Novo Holdings A/S
PR-M04-22-05Apr 07, 2022
Failed to load
Expansion
Novo Nordisk Invests in Upgrading and Expanding Production Facilities in Kalundborg
Novo Nordisk
PR-M02-20-NI-013-1753Feb 11, 2020
Failed to load
Drug Pricing
Novo Nordisk Launching Additional US Insulin Affordability Offerings in January 2020
Novo Nordisk
PA2138Sep 11, 2019
Failed to load
Sustainability
Novo Nordisk Turns the Switch On Renewable Energy
Emilie Branch
Pharma's Almanac
PAO-M05-19-NI-013May 10, 2019
Failed to load
Pediatric
Novo Nordisk Files for a Label Update for Fiasp® to the EMA and the FDA Seeking Approval for Use in Children and Adolescents
Novo Nordisk
PR-M03-19-NI-007Mar 04, 2019
Failed to load
Diabetes
Novo Nordisk to Use Priority Voucher for Diabetes Drug
Pharma's Almanac
PAO-M02-19-NI-004Feb 06, 2019
Failed to load
Acquisition
Ziylo Acquired by Novo Nordisk in Deal That Could Exceed US$800m
Unit DX Incubator
PR-M09-18-NI-069Sep 24, 2018
Failed to load
Patient Adherence
New Approach by Novo Nordisk Ties Pricing to Patient Behavior
Emilie Branch
Pharma's Almanac
PAO-M04-18-NI-017Apr 26, 2018
Failed to load
Drug Development
More Good News for Novo Nordisk’s Semaglutide and Weight Loss
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M03-18-NI-024Mar 23, 2018
Failed to load
Clinical Trials
Novo Nordisk Bags FDA Approval for New Diabetes Treatment
Nice Insight
PAO-M12-17-NI-024Dec 15, 2017
Failed to load
Drug Development
New Insulin Formulation Improves Mealtime Glycemic Control
Emilie Branch
Pharma's Almanac
PAO-M10-17-NI-011Oct 10, 2017
1 / 1